Merck & Co., Inc. is 23.1x more valuable than Axsome Therapeutics, Inc. by market capitalization ($293.16 B vs $12.68 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AXSM | MRK |
|---|---|---|
| Market cap | $12.68 B | $293.16 B |
| US-listed rank | #813 | #44 |
| Revenue (latest FY) | $638.50M | $65.01B |
| Net income (latest FY) | -$183.17M | $18.25B |
| Net margin | -28.7% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 634 | 996 |
Merck & Co., Inc. is 23.1x more valuable than Axsome Therapeutics, Inc. by market capitalization ($293.16 B vs $12.68 B).
In their latest fiscal years, Axsome Therapeutics, Inc. reported $638.50M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Axsome Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.